ARS Pharmaceuticals Inc
SPRY
Company Profile
Business description
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Contact
11682 El Camino Real
Suite 120
San DiegoCA92130
USAT: +1 858 771-9307
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
167
Stocks News & Analysis
stocks
10 best US growth stocks to buy for the long term
The stocks of these high-quality growth companies look undervalued today.
stocks
Higher fair value for overvalued ASX tech share
Underlying secular growth stronger than we thought.
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,102.10 | 11.70 | 0.13% |
| CAC 40 | 7,843.74 | 9.85 | -0.13% |
| DAX 40 | 23,521.89 | 117.52 | -0.50% |
| Dow JONES (US) | 46,315.27 | 172.85 | 0.37% |
| FTSE 100 | 9,232.35 | 15.68 | 0.17% |
| HKSE | 26,344.14 | 200.96 | -0.76% |
| NASDAQ | 22,631.48 | 160.75 | 0.72% |
| Nikkei 225 | 45,493.66 | 447.85 | 0.99% |
| NZX 50 Index | 13,141.54 | 90.12 | -0.68% |
| S&P 500 | 6,664.36 | 32.40 | 0.49% |
| S&P/ASX 200 | 8,810.90 | 11.40 | 0.13% |
| SSE Composite Index | 3,828.58 | 8.49 | 0.22% |